Premium
Independent dosimetric assessment of the model EP917 episcleral brachytherapy plaque
Author(s) -
Aryal Prakash,
Molloy Janelle A.,
Rivard Mark J.
Publication year - 2014
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.4892603
Subject(s) - brachytherapy , dosimetry , nuclear medicine , medicine , medical imaging , medical physics , radiology , radiation therapy
Purpose: To investigate the influence of slot design on dose distributions and dose‐volume histograms (DVHs) for the model EP917 plaque for episcleral brachytherapy.Methods: Dimensions and orientations of the slots were measured for three model EP917 plaques and compared to data in the Plaque Simulator (PS) treatment planning software (version 5.7.6). These independently determined coordinates were incorporated into the MCNP Monte Carlo simulation environment to obtain dose from the plaques in a water environment and in a clinical environment with ocular structures. A tumor volume was simulated as 5 mm in apical height and 11 mm in basal diameter. Variations in plaque mass density and composition; slot length, width, and depth; seed positioning; and Ag‐marker rod positioning were simulated to examine their influence on plaque central axis (CAX) and planar dose distributions, and DVHs.Results: Seed shifts in a single slot toward the eye and shifts of the 125 I‐coated Ag rod within the capsule had the greatest impact on CAX dose distribution. A shift of 0.0994 mm toward the eye increased dose by 14%, 9%, 4.3%, and 2.7% at 1, 2, 5, and 10 mm, respectively, from the inner sclera. When examining the fully‐modeled plaque in the ocular geometry, the largest dose variations were caused by shifting the Ag rods toward the sclera and shifting the seeds away from the globe when the slots were made 0.51 mm deeper, causing +34.3% and −69.4% dose changes to the outer sclera, respectively. At points along the CAX, dose from the full plaque geometry using the measured slot design was 2.4% ± 1.1% higher than the manufacturer‐provided slot design and 2.2% ± 2.3% higher than the homogeneous calculation of PS treatment planning results. The ratio of D 10 values for the measured slot design to the D 10 values for the manufacturer‐provided slot design was higher by 9%, 10%, and 19% for the tumor, inner sclera, and outer sclera, respectively. In comparison to the measured slot design, a theoretical plaque having narrower and deeper slots delivered 30%, 37%, and 62% lower D 10 doses to the tumor, inner sclera, and outer sclera, respectively.Conclusions: While the measured positions of the slots on the model EP917 plaque were in close agreement (<0.7 mm) with the PS values, small differences in the slot shape caused substantial differences in dose distributions and DVH metrics. Increasing slot depth by 0.1 mm decreased outer scleral dose by 20%, yet shifting the Ag rods in the seeds toward the globe by 0.1 mm increased outer scleral dose by 35%. The clinical medical physicist is advised to measure these types of plaques upon acceptance testing before clinical use to inspect slot shape and position for comparison with data used for treatment planning purposes.